Akcje

Kapitalizacja (USD)	1 891 707 930
Aktywa:	6 801 100 000
Cena:	27.86
Wskaźnik Altman Z-Score:	0.1 Słaby (wysokie ryzyko bankructwa)
Dywidenda:	0
P/E:	-4.1
Ilość akcji w obrocie:	72%
Średni wolumen:	1 442 956
Ilość akcji	67 900 500

Przychody TTM	2 815 700 000
Zobowiązania:	3 614 400 000
Przedział 52 tyg.:	22.05 - 49.45
Piotroski F-Score:	4 Umiarkowany (średnia jakość finansowa)
EPS:	-6.8
P/E branży:	29.7
Beta:	0.116
Raport okresowy:	2025-11-06
WWW:	https://www.quidelortho.com

Imie i Nazwisko	Stanowisko	Wynagrodzenie	Rok urodzenia
Mr. Robert J. Bujarski J.D.	Executive Vice President & Chief Operating Officer	961 261	1969
Mr. Joseph M. Busky CPA	Chief Financial Officer	890 626	1968
Mr. Michael S. Iskra	Executive Vice President & Chief Commercial Officer	870 929	1970
Ms. Michelle A. Hodges J.D.	Senior Vice President, General Counsel & Corporate Secretary	1 795 965	1963
Dr. Werner Kroll Ph.D.	Senior Vice President of Research & Development	1 026 686	1957
Ms. Tamara A. Ranalli	Molecular Diagnostics Business Unit Leader	0	1973
Mr. Brian J. Blaser	President, Chief Executive Officer & Director	0	1965
Ruben Argueta	Director of Investor Relations	0	0
Mr. William J. Ferenczy	Point of Care Business Unit Leader	0	1956

Symbol ETF	Ilość akcji	Wartość
IJR	4 185 278	96 345 094
IWM	1 716 806	39 520 874
VB	1 651 418	47 593 866
AVUV	1 643 160	39 912 356
VBR	1 054 354	30 386 482
IJS	658 313	15 154 360
SPSM	571 433	13 914 492
SLYV	372 361	9 161 857
DFAT	354 164	8 152 855
IWN	353 729	8 142 833
IHI	352 465	8 113 734
VTWO	345 316	9 952 007
SCHA	312 903	7 521 474
IWO	272 404	6 270 730
DFSV	261 655	6 023 298
VIOO	219 408	6 323 338
VHT	209 598	6 040 614
FNDA	196 826	4 721 769
DFAS	192 311	4 426 999
VIOV	134 128	3 865 568
AVSC	122 427	2 973 751
IUS3.DE	103 520	2 084 665
IDP6.L	103 520	2 383 019
ISP6.L	103 520	1 803 659
RWJ	96 183	2 336 285
XHE	93 420	2 340 816
DFAC	92 614	2 131 974
2B78.DE	87 596	1 763 998
DRDR.L	87 596	1 526 217
HEAL.L	87 596	2 016 458
ITOT	86 503	1 991 294
NUSC	69 038	2 896 834
PSCH	63 541	1 543 410
USVM	58 003	1 335 229
FNDX	46 450	1 121 323
DFUV	43 955	1 011 844
SCHB	41 675	1 008 473
AVUS	40 104	974 126
PRF	38 488	934 873
RSSL	34 591	796 284
FHLC	28 284	737 929
CSUSS.MI	28 089	565 645
CUS1.L	28 089	489 398
CUSS.L	28 089	646 599
SXRG.DE	28 089	565 645
ESML	27 837	676 160
VTWG	25 900	746 438
VTWV	25 393	731 826
BBSC	23 528	541 614
IJR.AX	23 457	881 753
ONEQ	23 035	600 983
VFVA	21 742	626 604
FYX	17 801	454 637
IWV	17 416	400 906
DFAU	16 072	369 977
HTEC	16 060	0
ESGV	14 425	415 728
TILT	12 986	298 937
XSU.TO	11 701	392 558
SPTM	11 284	274 558
QVMS	10 605	257 595
UMDV.AS	9 415	216 739
VVL.TO	9 151	359 862
VFMF	8 209	236 583
DCOR	7 521	173 133
UWM	6 863	157 986
SIXL	6 059	0
URTY	5 680	130 753
FYT	5 389	137 635
OMFS	5 250	127 522
XJR	5 238	127 231
VTHR	5 039	145 223
VALQ	4 995	547 087
FNDB	3 549	85 634
BTAL	3 480	386 026
ISCB	3 172	73 015
XUU.TO	2 786	93 481
VLU	2 781	67 931
AVSU	2 625	63 761
XSMC.TO	2 340	78 523
DTEC.L	2 327	42 189
DRUP.DE	2 327	48 766
UNIC.L	2 327	55 674
DXUV	2 197	50 574
XSMH.TO	2 165	72 633
STXK	1 892	43 553
DFSU	1 866	42 955
CBUG.DE	1 254	25 243
EWSA.AS	1 254	28 856
SAA	1 222	28 130
V3AL.L	1 110	31 990
V3AB.L	1 110	24 241
V3AA.L	1 110	31 990
FAB	1 030	26 306
SCDS	898	20 671
EKG	784	20 023
ESIX	509	12 434
XBAL.TO	474	15 886
MCDS	457	10 520
EBIT	437	10 621
XUH.TO	411	9 992
SPGM	101	2 456
HDG	82	1 887
XTR.TO	17	404
MMTM	5	121
6PSA.DE	0	67 673
PXS.TO	0	4 202
SC0K.DE	0	129 902
USML.L	0	175 675
RTYS.L	0	148 256
PSRF.L	0	5 866 673
PRUS.L	0	77 234
CDX	-18 947	-436 162
FTLS	-22 897	0

Wiadomości dla QuidelOrtho Corporation

Tytuł	Treść	Źródło	Aktualizacja	Link
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.	zacks.com	2025-05-15 14:50:24	Czytaj oryginał (ang.)
QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)	Despite a once promising future, QuidelOrtho Corporation's current prospects are unappealing. I rated QuidelOrtho as a "Buy" in July 2023, but the stock has since declined by ~60% as its growth has stagnated. On 05/07/2025 the company reported top and bottom-line beats for its Q1/2025 earnings, bumping its shares up >40%.	seekingalpha.com	2025-05-12 13:30:00	Czytaj oryginał (ang.)
QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand	Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.	zacks.com	2025-05-08 17:10:54	Czytaj oryginał (ang.)
QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript	QuidelOrtho Corporation (NASDAQ:QDEL ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Conor McNamara - RBC Capital Patrick Donnelly - Citi Andrew Brackmann - William Blair Jack Meehan - Nephron Research Lu Li - UBS Casey Woodring - JPMorgan Andrew Cooper - Raymond James Tycho Peterson - Jefferies Operator Welcome to the QuidelOrtho First Quarter 2025 Financial Results Conference Call and Webcast. At this time, all participant lines are in listen mode only.	seekingalpha.com	2025-05-07 23:56:03	Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates	QuidelOrtho (QDEL) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.44 per share a year ago.	zacks.com	2025-05-07 23:10:32	Czytaj oryginał (ang.)
QuidelOrtho Reports First Quarter 2025 Financial Results	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025. “We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model,” said Brian J. Blaser, President an.	businesswire.com	2025-05-07 20:05:00	Czytaj oryginał (ang.)
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN	The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.	zacks.com	2025-05-06 15:15:45	Czytaj oryginał (ang.)
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates	MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.	zacks.com	2025-05-01 12:30:38	Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Earnings Expected to Grow: Should You Buy?	QuidelOrtho (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.	zacks.com	2025-04-30 15:06:08	Czytaj oryginał (ang.)
Why QuidelOrtho (QDEL) Could Beat Earnings Estimates Again	QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.	zacks.com	2025-04-24 17:15:50	Czytaj oryginał (ang.)
QuidelOrtho to Report First Quarter 2025 Financial Results	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at.	businesswire.com	2025-04-23 20:30:00	Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Surges 10.1%: Is This an Indication of Further Gains?	QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.	zacks.com	2025-04-10 16:35:40	Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now	QDEL continues to witness growth on the back of its strong product portfolio.	zacks.com	2025-04-09 18:35:36	Czytaj oryginał (ang.)
QuidelOrtho Unveils Results Manager System to Streamline Testing	QDEL introduces the Results Manager System, a powerful tool designed to streamline diagnostic data management, enhance efficiency, and improve patient care.	zacks.com	2025-03-14 13:05:31	Czytaj oryginał (ang.)
QuidelOrtho® Introduces Results Manager™ System	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio. The QuidelOrtho Results Manager system.	businesswire.com	2025-03-10 11:00:00	Czytaj oryginał (ang.)
Why QuidelOrtho Stock Bounced More Than 4% Higher Today	Healthcare in vitro diagnostics company QuidelOrtho (QDEL 4.28%) attracted the right kind of attention from investors after posting its latest quarterly earnings report on Thursday. A rather encouraged market traded the company's shares up by more than 4% in response.	fool.com	2025-02-13 20:19:00	Czytaj oryginał (ang.)
QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract	Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024.	zacks.com	2025-02-13 13:57:12	Czytaj oryginał (ang.)
QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript	QuidelOrtho Corporation (NASDAQ:QDEL ) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Patrick Donnelly - Citi Bill Bonello - Craig-Hallum Lu Li - UBS Andrew Cooper - Raymond James Casey Woodring - JPMorgan Andrew Brackmann - William Blair Jose Ricardo - RBC Capital Markets Operator Welcome to the QuidelOrtho Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode.	seekingalpha.com	2025-02-12 21:50:17	Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates	QuidelOrtho (QDEL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $1.17 per share a year ago.	zacks.com	2025-02-12 20:41:07	Czytaj oryginał (ang.)
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 29, 2024. “We are pleased with our 2024 business performance and ended the year with positive momentum leading into 2025,” said Brian J. Blaser, President and Chief Execu.	businesswire.com	2025-02-12 18:05:00	Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now	QDEL continues to witness growth on the back of its strong product portfolio.	zacks.com	2025-01-30 13:56:17	Czytaj oryginał (ang.)
QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues	QDEL's preliminary fourth-quarter revenues align with the company's expectations.	zacks.com	2025-01-14 14:50:22	Czytaj oryginał (ang.)
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm	NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, QuidelOrtho insiders caused the company to misrepresent or fail to disclose that (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) excess inventories of COVID-19 tests existed throughout the supply chain; (c) as a result, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the United States; (e) as a result, the company lacked a reasonable basis for positive statements about QuidelOrtho's business, financials, and growth trajectory.	prnewswire.com	2025-01-07 02:48:00	Czytaj oryginał (ang.)
QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. The Company's presentation is scheduled for Monday, January 13, 2025 at 7:30 a.m. PST / 10:30 a.m. EST. Interested parties can access the live webcast.	businesswire.com	2024-12-31 09:00:00	Czytaj oryginał (ang.)
QuidelOrtho Announces Appointment of Two Independent Directors to its Board	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the “Board”), effective December 6, 2024. These appointments align with QuidelOrtho's commitment to maintaining a strong, independent Board with the ri.	businesswire.com	2024-12-10 09:00:00	Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now	QDEL continues to witness growth on the back of its strong product portfolio.	zacks.com	2024-12-04 15:30:29	Czytaj oryginał (ang.)
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted	On Tuesday, QuidelOrtho Corporation QDEL priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of 8.26 million shares.	benzinga.com	2024-11-20 17:08:36	Czytaj oryginał (ang.)
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session	U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.	benzinga.com	2024-11-20 10:06:51	Czytaj oryginał (ang.)
QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company's common stock (“Common Stock”). The Selli.	businesswire.com	2024-11-19 23:05:00	Czytaj oryginał (ang.)
QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company's common stock (“Common Stock”). The Selling Stockholder will rec.	businesswire.com	2024-11-19 18:54:00	Czytaj oryginał (ang.)
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm	NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, QuidelOrtho insiders caused the company to misrepresent or fail to disclose that (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) excess inventories of COVID-19 tests existed throughout the supply chain; (c) as a result, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the United States; (e) as a result, the company lacked a reasonable basis for positive statements about QuidelOrtho's business, financials, and growth trajectory.	prnewswire.com	2024-11-13 14:39:00	Czytaj oryginał (ang.)
QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates	QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.	zacks.com	2024-11-08 15:21:18	Czytaj oryginał (ang.)
QuidelOrtho Corporation (QDEL) Q3 2024 Earnings Call Transcript	QuidelOrtho Corporation (NASDAQ:QDEL ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Juliet Cunningham – Vice President, Investor Relations Brian Blaser – President and Chief Executive Officer Joe Busky – Chief Financial Officer Conference Call Participants Andrew Brackmann – William Blair Jack Meehan – Nephron Research Bill Bonello – Craig-Hallum Patrick Donnelly – Citi Andrew Cooper – Raymond James Jose Ricardo Moreno – RBC Capital Markets Casey Woodring – JPMorgan Operator Welcome to the QuidelOrtho Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode.	seekingalpha.com	2024-11-07 22:54:26	Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates	QuidelOrtho (QDEL) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.90 per share a year ago.	zacks.com	2024-11-07 21:41:06	Czytaj oryginał (ang.)
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm	NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders.	globenewswire.com	2024-10-31 16:17:00	Czytaj oryginał (ang.)
QuidelOrtho to Participate in Three Upcoming Investor Conferences	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences. UBS Global Healthcare Conference On Tuesday, November 12, 2024, QuidelOrtho is scheduled to part.	businesswire.com	2024-10-28 09:00:00	Czytaj oryginał (ang.)
QuidelOrtho to Report Third Quarter 2024 Financial Results	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its third quarter 2024 ended September 29, 2024, after the market close on Thursday, November 7, 2024. Following the release of financial results, QuidelOrtho will hold a conference call beginni.	businesswire.com	2024-10-17 11:00:00	Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now	QDEL's strong product portfolio raises optimism about the stock.	zacks.com	2024-10-08 17:42:10	Czytaj oryginał (ang.)
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer	SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key.	businesswire.com	2024-09-10 11:00:00	Czytaj oryginał (ang.)
Why QuidelOrtho Stock Blasted 10% Higher Today	An analyst became notably more bullish on the diagnostics company's prospects. He upgraded his recommendation from hold to buy.	fool.com	2024-09-05 21:25:23	Czytaj oryginał (ang.)
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now	QDEL's strong product portfolio raises optimism about the stock.	zacks.com	2024-09-03 14:46:11	Czytaj oryginał (ang.)
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod	QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.	zacks.com	2024-08-30 16:56:20	Czytaj oryginał (ang.)
QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue?	QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?	zacks.com	2024-08-30 16:36:29	Czytaj oryginał (ang.)

Sektor:	Zdrowie
Branża:	Medical - Instruments & Supplies
Zatrudnienie:	7 100
Giełda:	NASDAQ Global Select
Ilość akcji w obrocie:	71.9751
Ilość akcji:	Brak danych
Debiut giełdowy:	1991-02-01
WWW:	https://www.quidelortho.com
CEO:	Mr. Brian J. Blaser
Adres:	9975 Summers Ridge Road
Siedziba:	92121 San Diego
ISIN:	US2197981051

Notowania:

Opis firmy:

Informacje o spółce:

Wskaźniki finansowe

Wskaźniki finansowe

Zarząd

Lista ETF z ekspozycją na akcje QuidelOrtho Corporation

Wiadomości dla QuidelOrtho Corporation